<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">
Skip to content

Meet the Author

Yannis Jemiai

Chief Scientific Officer

Dr. Yannis Jemiai has a pivotal role within Cytel as Chief Scientific Officer. He has oversight for the corporate-level Scientific Agenda, which includes establishing research portfolios in Bayesian, small sample, and other flexible designs as well as complex innovative designs including adaptive trials, master protocols, and MAMS. Yannis also has an extensive portfolio of research in adaptive trial design, financial and pharmaceutical strategy, decision theory, and regulatory affairs. His own research has been published in numerous statistical journals. Yannis earned his Ph.D. from Harvard University, an M.P.H. from Columbia University, and a B.A. in Molecular and Cellular Biology also from Harvard.


Read all posts by this author 

Featured Posts

Sorry no results please clear the filters and try again

A Look Ahead for 2023

Returning to Cytel after the winter holidays, I am excited to begin a year that will likely prove memorable for both my...
Read more

New Dimensions of Clinical Trial Optimization

For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea...
Read more

What’s Ahead for Clinical Trial Design?

The past two years have been transformative for Cytel. Most notably, the global COVID-19 pandemic unleashed an...
Read more
Load more